Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

Similar articles for PubMed (Select 23410232)

1.

AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans.

Georgievska B, Sandin J, Doherty J, Mörtberg A, Neelissen J, Andersson A, Gruber S, Nilsson Y, Schött P, Arvidsson PI, Hellberg S, Osswald G, Berg S, Fälting J, Bhat RV.

J Neurochem. 2013 May;125(3):446-56. doi: 10.1111/jnc.12203. Epub 2013 Mar 11.

PMID:
23410232
2.

Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.

Franklin AV, King MK, Palomo V, Martinez A, McMahon LL, Jope RS.

Biol Psychiatry. 2014 Feb 1;75(3):198-206. doi: 10.1016/j.biopsych.2013.08.003. Epub 2013 Sep 13.

3.

Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A.

Martin L, Magnaudeix A, Esclaire F, Yardin C, Terro F.

Brain Res. 2009 Feb 3;1252:66-75. doi: 10.1016/j.brainres.2008.11.057. Epub 2008 Nov 30.

PMID:
19071093
4.

A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.

Onishi T, Iwashita H, Uno Y, Kunitomo J, Saitoh M, Kimura E, Fujita H, Uchiyama N, Kori M, Takizawa M.

J Neurochem. 2011 Dec;119(6):1330-40. doi: 10.1111/j.1471-4159.2011.07532.x. Epub 2011 Nov 2.

PMID:
21992552
5.

Okadaic acid-induced Tau phosphorylation in rat brain: role of NMDA receptor.

Kamat PK, Rai S, Swarnkar S, Shukla R, Ali S, Najmi AK, Nath C.

Neuroscience. 2013 May 15;238:97-113. doi: 10.1016/j.neuroscience.2013.01.075. Epub 2013 Feb 13.

PMID:
23415789
6.

Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation.

Selenica ML, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M, Lotharius J.

Br J Pharmacol. 2007 Nov;152(6):959-79. Epub 2007 Oct 1.

7.
8.

The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents.

van der Staay FJ, Rutten K, Bärfacker L, Devry J, Erb C, Heckroth H, Karthaus D, Tersteegen A, van Kampen M, Blokland A, Prickaerts J, Reymann KG, Schröder UH, Hendrix M.

Neuropharmacology. 2008 Oct;55(5):908-18. doi: 10.1016/j.neuropharm.2008.07.005. Epub 2008 Jul 12.

PMID:
18674549
9.

Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats.

Cai HY, Hölscher C, Yue XH, Zhang SX, Wang XH, Qiao F, Yang W, Qi JS.

Neuroscience. 2014 Sep 26;277:6-13. doi: 10.1016/j.neuroscience.2014.02.022. Epub 2014 Feb 27.

PMID:
24583037
10.

Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418.

Bhat R, Xue Y, Berg S, Hellberg S, Ormö M, Nilsson Y, Radesäter AC, Jerning E, Markgren PO, Borgegård T, Nylöf M, Giménez-Cassina A, Hernández F, Lucas JJ, Díaz-Nido J, Avila J.

J Biol Chem. 2003 Nov 14;278(46):45937-45. Epub 2003 Aug 19.

11.

Inhibition of glycogen synthase kinase-3 reverses tau hyperphosphorylation induced by Pin1 down-regulation.

Xiong YS, Wang DL, Tan L, Wang X, Chen LM, Gong CX, Wang JZ, Zhu LQ.

CNS Neurol Disord Drug Targets. 2013 May 1;12(3):436-43.

PMID:
23469846
12.

Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo.

Bitner RS, Nikkel AL, Markosyan S, Otte S, Puttfarcken P, Gopalakrishnan M.

Brain Res. 2009 Apr 10;1265:65-74. doi: 10.1016/j.brainres.2009.01.069. Epub 2009 Feb 20.

PMID:
19230830
13.

Subchronic MK-801 treatment and post-weaning social isolation in rats: differential effects on locomotor activity and hippocampal long-term potentiation.

Ashby DM, Habib D, Dringenberg HC, Reynolds JN, Beninger RJ.

Behav Brain Res. 2010 Sep 1;212(1):64-70. doi: 10.1016/j.bbr.2010.03.041. Epub 2010 Apr 9.

PMID:
20382186
14.

GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.

Hu S, Begum AN, Jones MR, Oh MS, Beech WK, Beech BH, Yang F, Chen P, Ubeda OJ, Kim PC, Davies P, Ma Q, Cole GM, Frautschy SA.

Neurobiol Dis. 2009 Feb;33(2):193-206. doi: 10.1016/j.nbd.2008.10.007. Epub 2008 Nov 5.

15.
16.

Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways.

Hu JP, Xie JW, Wang CY, Wang T, Wang X, Wang SL, Teng WP, Wang ZY.

Brain Res Bull. 2011 May 30;85(3-4):194-200. doi: 10.1016/j.brainresbull.2011.03.006. Epub 2011 Mar 22.

PMID:
21435383
17.

A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.

Serenó L, Coma M, Rodríguez M, Sánchez-Ferrer P, Sánchez MB, Gich I, Agulló JM, Pérez M, Avila J, Guardia-Laguarta C, Clarimón J, Lleó A, Gómez-Isla T.

Neurobiol Dis. 2009 Sep;35(3):359-67. doi: 10.1016/j.nbd.2009.05.025. Epub 2009 Jun 10.

PMID:
19523516
18.

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.

Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, Behar L, Ben-Hur T, Avraham Y, Berry E, Segal M, Ginzburg I, Abramsky O.

Exp Neurol. 2008 Jul;212(1):71-84. doi: 10.1016/j.expneurol.2008.03.007. Epub 2008 Mar 21.

PMID:
18490011
19.

Inhibition of GSK3 dependent tau phosphorylation by metals.

Gómez-Ramos A, Domínguez J, Zafra D, Corominola H, Gomis R, Guinovart JJ, Avila J.

Curr Alzheimer Res. 2006 Apr;3(2):123-7. Review.

PMID:
16611012
20.

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L.

J Biol Chem. 2001 Jan 5;276(1):251-60.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk